ReviewFrontiers in immunology2026

JAK1-preferential inhibition in refractory inflammatory bowel disease: reframing upadacitinib as a strategy for rapid immune recalibration.

Xiaowei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.